A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

This study tests a new drug called BDTX-1535 for people with brain tumors — either glioblastoma newly diagnosed or high-grade glioma that has come back after treatment — that have specific changes (mutations or fusions) in the EGFR gene. The drug is designed to cross the blood-brain barrier and target these specific genetic changes. **You may be eligible if...** - You have recurrent high-grade brain tumor (grades 3 or 4) that progressed after standard treatment, OR - You have newly diagnosed glioblastoma not yet treated beyond surgery or biopsy - Your tumor has a specific EGFR alteration or fusion confirmed by tissue testing - You are a candidate for surgery to remove or biopsy the tumor **You may NOT be eligible if...** - You have received prior treatment with certain EGFR-targeting drugs - You have serious organ problems or poor functional status - You cannot have the required surgery - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.